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Abstract
Neurological deterioration is common after intracerebral hemorrhage (ICH). We aimed to identify the predictors and effects of neurolog-
ical deterioration and whether tranexamic acid reduced the risk of neurological deterioration. Data from the Tranexamic acid in
IntraCerebral Hemorrhage-2 (TICH-2) randomized controlled trial were analyzed. Neurological deterioration was defined as an increase
in National Institutes of Health Stroke Scale (NIHSS) of ≥ 4 or a decline in Glasgow Coma Scale of ≥ 2. Neurological deterioration was
considered to be early if it started ≤ 48 h and late if commenced between 48 h and 7 days after onset. Logistic regression was used to
identify predictors and effects of neurological deterioration and the effect of tranexamic acid on neurological deterioration. Of 2325
patients, 735 (31.7%) had neurological deterioration: 590 (80.3%) occurred early and 145 (19.7%) late. Predictors of early neurological
deterioration included recruitment from the UK, previous ICH, higher admission systolic blood pressure, higher NIHSS, shorter onset-to-
CT time, larger baseline hematoma, intraventricular hemorrhage, subarachnoid extension and antiplatelet therapy. Older age, male sex,
higher NIHSS, previous ICH and larger baseline hematoma predicted late neurological deterioration. Neurological deterioration was
independently associatedwith amodifiedRankin Scale of > 3 (aOR4.98, 3.70–6.70; p< 0.001). Tranexamic acid reduced the risk of early
(aOR 0.79, 0.63–0.99; p=0.041) but not late neurological deterioration (aOR 0.76, 0.52–1.11; p= 0.15). Larger hematoma size, intra-
ventricular and subarachnoid extension increased the risk of neurological deterioration. Neurological deterioration increased the risk of
death and dependency at day 90. Tranexamic acid reduced the risk of early neurological deterioration andwarrants further investigation in
ICH. URL:https://www.isrctn.com Unique identifier: ISRCTN93732214
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Introduction
Neurological deterioration affects approximately one-third of pa-
tients with spontaneous intracerebral hemorrhage (ICH) and in-
creases the risk of death and dependency [1–3]. Older age, prior
use of anticoagulant, larger baseline hematoma, CT angiography
spot sign, hematoma expansion, perihematomal edema, intraven-
tricular hemorrhage, subarachnoid extension, hydrocephalus and
leukoaraiosis were reported to increase the risk of neurological
deterioration after ICH in previous studies [2–6]. Nevertheless,
apart from hematoma expansion, reports of other neurological
and systemic complications associated with neurological deteri-
oration were not well documented [2–6].
Tranexamic acid is an antifibrinolytic agent that was effec-
tive in preventing death due to bleeding in major trauma and
traumatic brain injury [7, 8]. In the Tranexamic acid in
Intracerebral Hemorrhage-2 (TICH-2) trial, there was no sig-
nificant difference in death and dependency at day 90 between
ICH patients treated with tranexamic acid and placebo [9].
However, there was a significant reduction in the rates of
hematoma expansion, early death and serious adverse events
with tranexamic acid [9].
Aims/Hypothesis
We aimed to examine the predictors of neurological deterio-
ration in ICH and the effects on day 90 clinical outcome. We
also explored the effect of tranexamic acid on neurological
deterioration in the first seven days after ICH.
Methods
The TICH-2 trial was a prospective multicentre randomized
placebo-controlled trial testing the efficacy and safety of in-
travenous tranexamic acid in patients with acute spontaneous
ICH presenting within eight hours of onset. Details of the trial
have been published [9, 10]. Approvals were obtained from
relevant national and institutional review boards prior to com-
mencement.Written consent was obtained from the patients or
their representatives prior to enrolment into the trial.
Definition of Neurological Deterioration
Neurological deterioration was defined a priori as an increase
in National Institutes of Health Stroke Scale (NIHSS) of ≥ 4
points or a decline in GCS of ≥ 2 points in our statistical
analysis plan [10], as assessed at baseline (pre-randomiza-
tion), day 2 and day 7. This definition with a cut-off of ≥ 4
points in NIHSS has a relatively high sensitivity and specific-
ity for mortality (0.909 and 0.907) as compared with a lower
NIHSS cut-off of ≥ 2 points (0.955, 0.685) [11]. In addition,
clinical neurological deterioration was defined as that reported
on the day 7 case report form, where investigators answered
“yes” or “no” to whether the patient had an increase in NIHSS
≥ 4 or a decline in GCS ≥ 2 in the first 7 days, and specified the
date it occurred. This reported neurological deterioration was
irrespective of changes in NIHSS/GCS between the timed
assessments (day 2 and day 7) because deterioration could
also be transient [12], the participant may have recovered after
treatment (e.g. neurosurgical intervention) or could not be
assessed due to intubation. Neurological deterioration was
considered early (END) if first occurred within the first 48 h,
and late (LND) if first occurred between 48 h and 7 days [1, 2].
The time neurological deteriorations occurred was specified
by the investigators in the day 7 form or serious adverse event
(SAE) reports.
Imaging Analysis
Measurements of hematoma, intraventricular hemorrhage and
perihematomal edema (PHE) volumes were performed by
three independent raters blinded to clinical data using semi-
automated segmentation tools of ITK-SNAP software version
3.6.0 [13, 14]. Radiological adjudication including location of
hematoma and presence of IVH was performed by a group of
qualified neuroradiologists. Hematoma expansion was de-
fined as an increase in intraparenchymal hematoma volume
on follow-up scan (at 24 h) of > 33% or > 6 mL from baseline
volume. Hematoma progression was defined as a composite
of intraparenchymal, intraventricular or subarachnoid hemor-
rhagic expansion, or in case follow-up scans were not avail-
able, the occurrence of END or death before day-2 clinical
assessment [15].
Serious Adverse Events Reporting and Adjudication
Serious adverse events (SAE) were any events that were life-
threatening, resulted in death, disability, hospitalization or
prolongation of existing hospitalization or considered medi-
cally important. All SAEs were reported in the first 7 days,
while fatal SAEs and safety outcomes (arterial and venous
thrombosis and seizures) were reported up to 90 days. All
SAEs including neurological deterioration were adjudicated
by assessors who were consultant stroke physicians, based
on clinical and diagnostic information provided by
investigators.
Statistical Analysis
Baseline characteristics of patients with END or LND were
compared with those with no neurological deterioration.
Multivariable binary logistic regression analyses were per-
formed to determine the predictors of END and LND and their
effect on outcomes. Variables that were significant on
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univariate analyses (p < 0.05) were included in the models. To
determine the effects of tranexamic acid on END and LND,
multivariable binary logistic regression analyses were per-
formed with adjustment of covariates, as prespecified in the
primary publication and statistical analysis plan with addition
of baseline hematoma volume [9, 10]. These covariates were
chosen as they were minimization factors and stratification
used during randomization (age, sex, systolic blood pressure,
NIHSS, onset-to-randomization time, prior antiplatelet thera-
py, country of recruitment and intraventricular hemorrhage).
Baseline hematoma volume, though not available at random-
ization, was included as well, as it is a known key prognostic
factor. p of < 0.05 was considered statistically significant and
95% confidence intervals (CI) are given. Analyses were per-
formed using Statistical Package for the Social Sciences
(SPSS) version 26 (IBM, Armonk, NY).
Data Availability Statement
The trial data can be shared, upon reasonable request to the
corresponding author and trial steering committee.
Results
Of the 2325 patients recruited into the trial, data on neurological
status was available in 2317 (99.7%). Seven hundred thirty-five
patients (31.7%) had neurological deterioration within 7 days
from onset of ICH. These include 590 patients with increase in
NIHSS ≥ 4 or decline in GCS ≥ 2 (336 with an increase in
NIHSS ≥ 4 only and 479 with decline in GCS ≥ 2 only; 225 with
both an increase in NIHSS ≥ 4 and a decline in GCS ≥ 2). In 145
patients, the occurrence of neurological deterioration was based
on the day 7 case report form, where investigators confirmed that
there was a change in NIHSS or GCS fulfilling the definition but
did not provide the actual scores. END and LND occurred in 590
(25.5%) and 145 (6.3%) respectively. The timings of neurolog-
ical deterioration were recorded in 716 patients, including in all
590 with END (≤ 6 h 134, 5.8%; 6–24 h 282, 12.2%; 24–48 h
174, 7.5%) and 126/145 of LND. In 19 patients with LND, there
was a change in NIHSS or GCS fulfilling the definition for
neurological deterioration but the time the neurological deterio-
ration occurred was not recorded.
Patients with END and LND were likely to be older, have
previous ischemic stroke, intracerebral hemorrhage, ischemic
heart disease, antiplatelet therapy, more severe stroke at onset
(higher NIHSS, lower GCS) and a raised leukocyte count or
blood glucose (Table 1). Patients with neurological deteriora-
tion were more likely to be issued with a “do not attempt
resuscitation” (DNAR) order in the first 7 days (369, 50.2%
vs 137, 8.8%; p < 0.001; Table 1). Of the 369 patients with
neurological deterioration and DNAR order, in 114 (30.9%) a
DNAR order was issued at least one day before neurological
deterioration occurred while a DNAR order was issued on the
same day in 167 (45.3%) or after neurological deterioration
occurred in 82 (22.2%); the timing was missing in 6 (1.6%)
patients. While the date of DNAR order issue was recorded,
the time was not, so it is not clear whether DNAR was issued
before or after neurological deterioration in patients who had
DNAR issued on the same day as deterioration. The propor-
tion of patients who had neurosurgery, invasive ventilation
and intensive care unit admission was higher in patients with
neurological deterioration (Table 1). There were higher pro-
portions of death within 48 h in patients with END and within
7 days in patients with END and LND compared with patients
with no neurological deterioration (Table 1). Notably, of 97
patients who died ≤ 48 h, 96 (99%) had END prior to death.
Both END and LND were associated with intraventricular
hemorrhage, subarachnoid extension, lobar location, larger
baseline hematoma and edema volume, midline shift and
leukoaraiosis on CT (Table 2). Patients with END and LND
had significantly more hematoma expansion and edema
growth (Table 2).
Multivariable logistic regression analysis showed that recruit-
ment from the UK, admission systolic blood pressure, NIHSS,
prior antiplatelet therapy, previous ICH, onset-to-CT time, base-
line hematoma volume, midline shift, intraventricular hemor-
rhage and subarachnoid extensionwere independently associated
with END (Table 3). The strongest predictors of END were
previous ICH (adjusted odds ratio [aOR] 2.62; 95%CI 1.58–
4.34; p < 0.001), recruitment from the UK (UK, aOR 2.40,
95%CI 1.62–3.56; p < 0.001) and subarachnoid extension
(aOR 2.06, 95%CI 1.44–2.94; p < 0.001). A comparison of char-
acteristics betweenUK and non-UK showed that patients recruit-
ed from the UK were older, more likely to have previous stroke
and intracerebral hemorrhage, lobar hematoma, intraventricular
hemorrhage, larger baseline hematoma volume, shorter onset to
randomization and also more likely to be issued with a DNAR
order in the first week (Supplemental Table 1). For every 10 mL
increase in baseline hematoma volume, the risk of END in-
creased by 21% (aOR 1.21, 95%CI 1.12–1.32; p < 0.001). The
predictors of LND were older age, male sex, previous intracere-
bral hemorrhage, higher NIHSS and larger baseline hematoma
volume (Table 3).
We further explored if a DNAR order was associated with
less active care and its effect on neurological deterioration.
Patients with DNAR in the first 7 days were less likely to
undergo neurosurgery (13, 2.6% vs 107, 5.9%; p = 0.003,
chi-squared test), intensive care unit admission (38, 7.5% vs
92, 10.6%; p = 0.036), received antihypertensive agent(s)
(364, 71.9% vs 1553, 86.3%; p < 0.001) but had similar inva-
sive ventilation (34, 6.7% vs 130, 7.2%; p = 0.72) compared
with those with no DNAR order. Of the 223 patients who died
in the first 7 days, 204 (91.5%) had a DNAR order issued, 18
(8.1%) had not while the status was unknown in one patient.
We performed sensitivity analyses for predictors of END and
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LND by excluding patients with DNAR at day 2 and day 7
respectively in the logistic regression model (Supplemental
Table 2). Similar to the full model (Table 3), significant pre-
dictors of END were recruitment from the UK, admission
systolic blood pressure, NIHSS, prior antiplatelet therapy,
previous ICH, onset-to-CT time, baseline hematoma volume,
midline shift, intraventricular hemorrhage and subarachnoid
extension, with the strongest being previous ICH (aOR 2.74;
95%CI 1.44–5.19; p = 0.002), recruitment from the UK (aOR
1.91, 95%CI 1.23–3.05; p = 0.004), subarachnoid extension
Table 1 Comparison of clinical
characteristics by neurological
deterioration status
Characteristics Early neurological
deterioration (n = 590)
No
deterioration
(n = 1582)
p
valuea
Late neurological
deterioration
(n = 145)
p
valueb
Age (years) 72.4 (13.4) 67.3 (13.7) < 0.001 72.9 (12.2) < 0.001
Sex (male) 300 (50.8) 904 (57.1) 0.009 92 (63.4) 0.14
Country,
UK 543 (92.0) 1246 (78.8) < 0.001 114 (78.6) 0.97
Non-UK 47 (8.0) 336 (21.2) 31 (21.4)
Premorbid mRS
(/5)
0 [0, 1] 0 [0, 0] < 0.001 0 [0, 1] 0.097
Admission SBP
(mmHg)
176.8 (30.9) 174.4 (29.6) 0.098 172.1 (27.5) 0.37
GCS (/15) 13 [11, 15] 15 [13, 15] < 0.001 14 [11, 15] < 0.001
NIHSS (/42) 18 [11, 22] 10 [5, 16] < 0.001 17 [11.5, 20] < 0.001
Antiplatelet
therapy
216 (36.7) 343 (21.7) < 0.001 50 (34.5) < 0.001
Previous ischemic
stroke/TIA
105 (18.1) 196 (12.4) 0.001 29 (20.9) 0.005
Previous ICH 52 (8.9) 61 (3.9) < 0.001 12 (8.3) 0.011
Ischemic heart
disease
68 (11.8) 118 (7.5) 0.002 17 (12.2) 0.047
Hypertension 361 (62.3) 965 (61.1) 0.60 90 (62.5) 0.75
Diabetes mellitus 80 (13.7) 204 (12.9) 0.63 26 (18.1) 0.082
Atrial fibrillation 16 (2.8) 47 (3.0) 0.79 8 (5.6) 0.081
Onset-to-CT time
(hours)
2.1 (1.1) 2.3 (1.4) 0.001 2.4 (1.2) 0.52
Raised leukocyte
countc
131 (22.9) 250 (16.1) < 0.001 38 (26.6) 0.001
Temperature
> 37.5 °C
14 (2.5) 43 (2.8) 0.72 2 (1.4) 0.35
Glucose (mmol/L) 7.5 (2.7) 7.1 (2.8) 0.012 7.6 (2.7) 0.050
Management within 7 days
Tranexamic acid 283 (48.0) 807 (51.0) 0.21 66 (45.5) 0.20
Antihypertensive
agent(s)
429 (73.6%) 1367 (86.6%) < 0.001 121 (83.6%) 0.29
DNAR, day 2 251 (42.5%) 107 (6.8%) < 0.001 31 (21.4%) < 0.001
DNAR, day 7 316 (53.6%) 137 (8.8%) < 0.001 53 (36.5%) < 0.001
Neurosurgery 83 (14.1%) 24 (1.5%) < 0.001 14 (9.7%) < 0.001
Invasive
ventilation
114 (19.5) 25 (1.6%) < 0.001 27 (18.9%) < 0.001
Intensive care 130 (22.1%) 67 (4.2%) < 0.001 35 (24.1%) < 0.001
Outcome
Death ≤ 48 h 96 (16.3%) 1 (0.1%) < 0.001 0 (0) -
Death ≤ 7 days 196 (33.4%) 8 (0.5%) < 0.001 18 (12.4%) < 0.001
Data are number (%), median [interquartile range] or mean (standard deviation). Statistics are t-Student, Mann-
Whitney U and chi-squared test: a comparison of early neurological deterioration and no deterioration;
b comparison of late neurological deterioration and no deterioration. c Leukocyte count of > 11.0 × 109 /L was
considered to be raised. CT, computed tomography; DNAR, do not attempt resuscitation; NIHSS, National
Institutes of Health Stroke Scale; TIA, transient ischemic attack
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(aOR 2.06, 95%CI 1.44–2.94; p < 0.001) and midline shift
(aOR 1.93, 95%CI 1.19–3.13; p = 0.008). Older age, previous
intracerebral hemorrhage, higher NIHSS and larger baseline
hematoma volume predicted LND.
Tranexamic acid significantly reduced the risk of neurological
deterioration within 7 days (aOR 0.79, 95%CI 0.64–0.97; p =
0.026) and END (aOR 0.79, 95%CI 0.63–0.99; p= 0.041) but
not LND (Table 4). Tranexamic acid reduced the risk of hema-
toma expansion (aOR0.76, 0.62–0.93; p= 0.008) and hematoma
progression (aOR 0.71, 0.59–0.86; p < 0.001) but not edema
growth at 24 h. There was no significant difference in reported
cerebral and non-cerebral events between the treatment groups
(Table 4). Sensitivity analyses excluding patients with DNAR
order yielded similar results where tranexamic acid reduced the
risk of neurological deterioration within 7 days, END, hematoma
expansion and hematoma progression (Supplemental Table 3).
Neurological deteriorations were reported as SAEs in 660
(89.8%) with 75 (10.2%) not reported. A full list of SAEs that
resulted in neurological deterioration is given in Supplemental
Table 4. Most END (499, 84.6%) was related to a cerebral SAE,
with hematoma expansion (256, 43.4%) as the most common
cause. Only 6.6% (n= 39) of ENDwas attributed to non-cerebral
SAE. A majority of LND was attributed to a cerebral SAE (79,
54.5%), but of these only 11.7% (n = 17) were hematoma expan-
sion with 11.0% (n= 16) attributed to cerebral edema.More than
one-fifth (33, 22.8%) of LND was attributed to medical compli-
cations, the highest being pneumonia (51, 6.9%). In 166 (22.6%)
patients with neurological deterioration, the cause was not spec-
ified (Supplemental Table 4).
Table 2 Comparison of
radiological findings by
neurological deterioration status
Radiological
findings
Early neurological
deterioration
(n = 590)
No
deterioration
(n = 1582)
p
valuea
Late neurological
deterioration
(n = 145)
p
valueb
Baseline CT
CT available 576 (97.6) 1550 (98.0) 139 (95.9)
Lobar hematoma 260 (44.6) 368 (23.7) < 0.001 55 (38.5) < 0.001
IVH 272 (46.3) 367 (23.6) < 0.001 67 (46.9) < 0.001
Hematoma
volume (mL)
42.8 (34.1) 15.7 (18.5) < 0.001 38.3 (31.6) < 0.001
IVH volume
(mL)
5.2 (11.2) 2.1 (6.3) < 0.001 6.7 (11.7) < 0.001
Subarachnoid
extension
150 (25.6) 123 (7.9) < 0.001 25 (17.5) < 0.001
PHE volume
(mL)
21.8 (20.7) 9.1 (10.8) < 0.001 18.7 (17.2) < 0.001
Midline shift
≥ 5 mm
206 (35.8) 124 (8.0) < 0.001 40 (28.8) < 0.001
Leukoaraiosis 325 (55.5) 654 (41.9) < 0.001 75 (52.4) 0.015
Old vascular
lesion
346 (59.0) 951 (61.0) 0.42 93 (65.0) 0.34
Cerebral atrophy 530 (90.4) 1428 (91.5) 0.42 135 (94.4) 0.23
24-h CT
CT available
(baseline and
24 h)
457 (77.5) 1483 (93.7) 134 (92.4)
Hematoma
expansion
269 (58.9) 260 (17.5) < 0.001 39 (29.1) 0.001
New IVHc 81 (16.2) 80 (5.3) < 0.001 18 (13.0) 0.001
Change in
hematoma
volume (mL)
15.9 (26.8) 1.5 (5.9) < 0.001 4.3 (10.8) 0.004
Change in
midline shift
(mm)
2.3 (4.6) 0.3 (2.7) < 0.001 0.6 (2.9) 0.30
Change in PHE
volume (mL)
13.4 (18.8) 4.3 (7.8) < 0.001 7.9 (13.2) < 0.001
Data are number (%) or mean (standard deviation). Statistics are t-Student and chi-squared tests: a comparison of
early neurological deterioration and no deterioration; b comparison of late neurological deterioration and no
deterioration. c Findings of intraventricular hemorrhage on 24-h CT when the baseline CT did not show any
intraventricular hemorrhage. IVH, intraventricular hemorrhage; PHE, perihematomal edema
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Table 3 Logistic regression
analyses for predictors of
neurological deterioration
Variables Early neurological deterioration Late neurological deterioration
Adjusted OR
(95%CI)
p Adjusted OR
(95%CI)
p
Age (years) 1.006 (0.994–1.018) 0.32 1.024 (1.005–1.043) 0.012
Sex (male) 1.09 (0.84–1.43) 0.51 1.59 (1.03–2.45) 0.037
Country (UK) 2.40 (1.62–3.56) < 0.001 0.89 (0.55–1.43) 0.63
Premorbid modified Rankin Scale 1.07 (0.94–1.21) 0.30 1.02 (0.84–1.24) 0.82
Systolic blood pressure (mmHg) 1.008 (1.004–1.013) < 0.001 1.003 (0.996–1.010) 0.37
National Institutes of Health Stroke
Scale
1.05 (1.03–1.07) < 0.001 1.04 (1.00–1.07) 0.043
Onset-to-CT time (hours) 0.83 (0.74–0.93) 0.001 0.98 (0.83–1.15) 0.80
Previous antiplatelet therapy 1.77 (1.33–2.37) < 0.001 1.16 (0.73–1.84) 0.53
Previous intracerebral hemorrhage 2.62 (1.58–4.34) < 0.001 2.98 (1.39–6.42) 0.005
Intraventricular hemorrhage 1.57 (1.19–2.07) 0.001 1.40 (0.91–2.15) 0.13
Subarachnoid extension 2.06 (1.44–2.94) < 0.001 1.36 (0.73–2.52) 0.33
Lobar location 1.28 (0.89–1.82) 0.18 0.82 (0.45–1.49) 0.51
Hematoma volume (per 10 mL
increase)
1.21 (1.12–1.32) < 0.001 1.26 (1.10–1.42) < 0.001
PHE volume (per 10 mL increase)a 1.10 (0.98–1.24) 0.095 1.06 (0.89–1.27) 0.55
Midline shift ≥ 5 mm 1.74 (1.21–2.51) 0.003 1.35 (0.77–2.37) 0.29
Leukoaraiosis 1.31 (0.99–1.73) 0.059 0.98 (0.63–1.52) 0.93
Raised leukocyte count
(> 11.0 × 109/L)
0.95 (0.68–1.32) 0.74 1.07 (0.65–1.76) 0.79
Glucose (mmol/L) 1.02 (0.98–1.06) 0.36 1.04 (0.97–1.11) 0.27
All variables significant on univariate analysis were entered into the models. PHE, perihematomal edema
a Refers to baseline volume. In an alternativemodel, day 2 PHE volumewas similarly not a significant predictor of
LND (aOR 1.10 per 10 mL, 95%CI 0.96–1.26; p = 0.17)
Table 4 Effect of tranexamic acid
on neurological deterioration,
serious adverse events and
radiological outcomes
Tranexamic acid Placebo MD/OR (95%CI) p
Neurological deteriorationa
All ≤ 7 days 338 (29.1) 366 (31.4) 0.79 (0.64, 0.97) 0.026
Early (< 48 h) 275 (23.7) 291 (25.0) 0.79 (0.63, 0.99) 0.041
Late (48 h to 7 days) 63 (7.1) 75 (8.6) 0.76 (0.52, 1.11) 0.15
SAE with neurological deterioration ≤ 7 daysb
Cerebral events 274 (23.6) 304 (26.1) 0.87 (0.72, 1.06) 0.16
Non-cerebral events 33 (2.8) 39 (3.4) 0.84 (0.53, 1.35) 0.48
Radiological outcomesa
Hematoma expansionc 265 (25.5) 305 (29.3) 0.76 (0.62, 0.93) 0.008
Hematoma progression 462 (40.1) 533 (45.9) 0.71 (0.59, 0.86) < 0.001
PHE growth (mL) 6.8 (11.8) 6.6 (12.7) − 0.17 (− 1.15, 0.80) 0.73
Hematoma expansion was defined as an increase in hematoma volume of > 33% or > 6 mL on follow-up scan
compared with baseline. Perihematomal edema (PHE) growth is the absolute difference in PHE volume between
follow-up and baseline scans. a Adjusted for age, sex, country of recruitment, admission systolic blood pressure,
previous antiplatelet therapy, National Institutes of Health Stroke Scale, onset-to-randomization time, intraven-
tricular hemorrhage and baseline hematoma volume. bUnadjusted. c Figure differed from previously published [9]
as current analysis included additional clinical scans, and radiological findings of hematoma location and presence
of intraventricular hemorrhage was based on expert adjudication rather than investigator reported. MD, mean
difference; OR, odds ratio; SAE, serious adverse event
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Neurological deterioration was associated with an in-
creased risk of death at day 7 (aOR 34.27) as well as death
(aOR 8.25) and death or dependency at day 90 (aOR 4.98)
(Table 5). Neurological deterioration resulted in worse disabil-
ity, cognition, depression and quality of life scores at day 90
compared with patients with no neurological deterioration
(Table 5). Neurological deterioration increased the risk of
death and dependency regardless of whether it was early
(aOR 5.18, 3.72–7.22; p < 0.001) or late deterioration (aOR
4.06, 2.35–7.03; p < 0.001). Similarly, disability, cognition,
depression and quality of life scores were all worse in patients
with END and LND compared with patients with no deterio-
ration (Supplemental Table 5 and 6).
Discussion
In this secondary analysis of one of the largest trials in acute ICH,
significant predictors of END were recruitment from UK, higher
admission SBP, higher NIHSS, previous ICH, antiplatelet thera-
py, shorter onset-to-CT time, intraventricular hemorrhage, sub-
arachnoid extension, larger hematoma volume and midline shift.
Older age, male sex, higher NIHSS, previous ICH and larger
hematoma volume predicted LND. This is in agreement with
previous findings, where patients with more severe stroke and
larger hematoma were more likely to suffer from neurological
deterioration [1–3, 5, 16]. Treatment with tranexamic acid was
associated with reduced END but not LND.
Several predictors of neurological deterioration, i.e. baseline
hematoma volume, antiplatelet therapy and shorter onset-to-CT
timewere also known predictors of hematoma expansion [17]. In
addition, hematoma expansion was more than 3 times more
common in patients with END compared with those with no
neurological deterioration (58.9% vs 17.5%). Patients with no
neurological deterioration hadminimal change in hematoma vol-
ume (1.5 mL) at 24 h while the absolute increase in hematoma
volume was significantly greater in patients with neurological
deterioration (16 mL). Our results reaffirm previous findings that
hematoma expansion was a main contributing factor to neuro-
logical deterioration [2–4]. Hematoma expansionwas not includ-
ed in the prediction model as this was not a baseline variable,
hence the difficulty in establishing the temporal relation between
hematoma expansion and neurological deterioration.
Intraventricular and subarachnoid hemorrhages may be asso-
ciated with complications of hydrocephalus or inflammation,
contributing to neurological deterioration [18]. Association of
subarachnoid extension with END was similarly described in
the INTERACT-2 trial and may be attributable to a higher risk
of hematoma expansion [6, 16]. PHE at baseline and 24 h was
not associated with neurological deterioration. Previous studies
showed that larger PHEvolumes did not alwaysworsen outcome
[19]. Early PHE may be a marker of clot retraction, a hemostatic
process which may improve outcome later [20]. Our study did
not explore the mechanisms of PHE or its evolution when it
continues to grow two to three weeks after ICH [21].
Another significant finding in this study was that patients
recruited from the UK had more END than those recruited
outside the UK. This may be because patients recruited from
the UKwere older, with a higher proportion who had previous
stroke, ICH, antiplatelet therapy, intraventricular hemorrhage
and larger hematoma volume. As previous epidemiological
studies have not indicated a higher case fatality rate of ICH
in the UK [22, 23], this may reflect a trial-specific recruitment
pattern where UK investigators were more likely to use brief
emergency consent (29% vs 6% in non-UK). The use of full
consent, which prolonged the time to randomization, may
have excluded some patients with more severe stroke who
may have deteriorated while consent was being sought.
Table 5 Effect of neurological
deterioration on day 90 outcome Outcomes Neurological
deterioration
No neurological
deterioration
OR/MD 95%CIa p
Day 7, death 214 (29.1) 9 (0.6) 34.27 (16.83,
69.80)
< 0.001
Day 90
Death 380 (52.0) 117 (7.5) 8.25 (6.12,
11.10)
< 0.001
Modified Rankin Scale > 3 636 (87.0) 618 (39.4) 4.98 (3.70, 6.70) < 0.001
Barthel Index 17.5 (34.7) 69.9 (37.2) − 29.4 (− 32.4,
− 26.5)
< 0.001
EuroQoL-5D Health Utility
Scores
0.09 (0.27) 0.46 (0.39) − 0.19 (− 0.23,
− 0.16)
< 0.001
Telephone Interview
Cognitive Status
2.1 (8.0) 20.1 (10.0) − 10.0 (− 11.1,
− 8.9)
< 0.001
Zung Depression Scale 93.6 (21.7) 53.6 (23.5) 22.1 (19.3, 24.9) < 0.001
aAdjusted for age, sex, country of recruitment, previous antiplatelet therapy, National Institutes of Health Stroke
Scale, admission systolic blood pressure, onset-to-randomization time, baseline hematoma volume, intraventric-
ular hemorrhage and treatment with tranexamic acid
Transl. Stroke Res.
DNAR order may limit active medical care, contributing to
worse outcome [24] which manifest initially as neurological
deterioration. However, the temporal relation between DNAR
order and neurological deterioration was unclear in a large
proportion of patients in this study. It is possible that DNAR
orders were issued in response to neurological deterioration
and may not be causal. Hence, we have not included DNAR
status in the main analyses for predictors of END and LND.
Excluding patients with DNAR order in the sensitivity analy-
ses did not affect the significance of the other predictors.
In our study, tranexamic acid had a modest effect in reducing
hematoma expansion at 24 h and END but not LND. This sug-
gests that tranexamic acid may have reduced END through pre-
vention of fibrinolysis. The role of fibrinolysis in ICHwas further
supported by a substudy of this trial, which showed elevated
plasminogen activators in patients with hematoma growth [25].
The effect of tranexamic acid on reduction of hematoma expan-
sion may have resulted in patients with smaller hematoma vol-
ume and less severe ICH who were less likely to suffer from
complications later. Tranexamic acid, which is mostly eliminated
after 24 h [26], could not have had an effect on events that
occurred beyond its therapeutic window such as worsening
PHE and medical complications. Hence, the early benefit of
tranexamic acid was not sufficient to result in a significant reduc-
tion in LND or improved functional outcome at day 90. The
recent Hemorrhagic Stroke Academia Industry (HEADS)
Roundtable recommended a multimodal approach to ICH trials,
combining hemostatic therapies with anti-edema agent(s) due to
these reasons [27]. In addition, tranexamic acid had been shown
to have some anti-inflammatory properties in clinical studies [28]
and perhaps repeated dosing of tranexamic acid could reduce
edema apart from promoting hemostasis.
Neurological deterioration, whether early or late, was asso-
ciated with significantly higher risk of death at days 7 and 90
as well as death and dependency and worse disability, cogni-
tion, depression and quality of life scores. This highlights the
need to better study, prevent and treat possible causes of neu-
rological deterioration in clinical and research settings.
The strength of our study is the large sample size. Using an
inclusive definition, we were able to determine if neurological
deterioration occurred in almost all patients. However, therewere
difficulties in attributing a cause in one-fifth of neurological de-
terioration and missing follow-up scans in nearly one-fourth of
participants with END. Routine neuroimaging was not per-
formed beyond 24 h making the study of possible mechanism
for LND including PHE suboptimal. As amajority of the patients
were recruited from the UK, who were different compared with
patients from other countries, caution should be taken in gener-
alizing the findings. Lastly, as these were post hoc analyses,
some findings may be due to chance arising from multiplicity
of testing. In the analyses on the effects of tranexamic acid, we
endeavoured to reduce type 1 error by including variables spec-
ified a priori in the statistical analysis plan [10].
In conclusion, neurological deterioration increased the risk
of death and dependency at day 90. Tranexamic acid reduced
the risk of END, probably through reduction of hematoma
expansion and warrants further investigation. More studies
are needed to understand the mechanisms leading to neuro-
logical deterioration in ICH.
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